Invitae Corporation (NYSE:NVTA) shares are trading lower this Wednesday after the company reported fourth-quarter financial results and provided guidance for full-year 2023. The company also announced ...

Outcomes4Me Inc., developer of a leading free mobile app and platform to navigate cancer treatment and care, has partnered with Invitae Corp., a leading medical genetics company, to expand education ...

This week, Invitae put out a press release highlighting the insights Praxis Precision Medicines was getting from Invitae's Citizen platform. The platform enables companies to get medical history data ...

After several tireless days we have finished crunching the numbers from nearly 900 13F filings issued by the elite hedge funds and other investment firms that we track at Insider Monkey, which ...

SEATTLE, July 22, 2021 /PRNewswire/ — Volpara Health, a global health technology software leader providing an integrated breast care platform for the delivery of personalized breast care, has signed ...

SAN FRANCISCO, Oct. 5, 2020 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading genetics company, today announced that on October 2, 2020, it completed the transaction to bring ArcherDX, a ...

Invitae Corporation (NYSE: NVTA), which specializes in medical genetic testing, saw its shares climb as high as 23% this week, according to data from S&P Global Intelligence. The stock closed at $2.30 ...

A little more than two years after California genetics-testing company Invitae Corp. (NYSE: NVTA) bought ArcherDX Inc., a Boulder developer of genetic assays for cancer patients, for $1.4 billion, ...

Hi, everyone. Good afternoon. Thanks for joining us here. If you don't know me, my name is Andrew Brackmann, I cover diagnostics for William Blair. This afternoon, we have Invitae joining us. We have ...

Shares of Invitae Corp. traded 40% higher after the company reported it will acquire ArcherDX in a combination cash and stock deal valued at around $1.4 billion. Advanced medical genetics company ...